This latest accomplishment joins the company’s previously secured ASTM certifications, enhancing the features and expanding the end-uses for its microalgae-based bio-cement and bio-concrete. BOULDER, ...

Having some free time following the $10.8 billion buyout of Prometheus Biosciences made Mark McKenna realize he had some “unfinished business.” Prometheus had managed to create a therapeutic that ...

Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue ...

Prometheus Biosciences contends that the current treatments for inflammatory bowel disease are inadequate, taking a “one-size-fits-all approach” that doesn’t account for biologic variation. The ...

Cement production accounts for 8 percent of annual CO2 emissions and consumes 9 percent of annual industrial water on a global basis, making reducing cement’s impact on climate change a huge challenge ...

Nearly a year after Prometheus Biosciences Inc. sold for $10.8 billion to Merck & Co. Inc., its former CEO, Mark McKenna, is back in the game with Mirador Therapeutics Inc. Many of his former ...